PLUS1
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 4.26 ▼ -0.01 (-0.23%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Sorrento Therapeutics Inc | SRNE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.08 | 1.91% | 4.27 | 4.29 | 4.10 | 4.21 | 4.19 | 23:59:37 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 4.19 | 4.40 | 0.21 | 4.77% | 3 | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 10,741 | 3,698,118 | $ 4.17 | $ 15,422,526 | 5,837,344 | 1.39 - 6.50 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:33 | 40 | $ 4.29 | USD |
Sorrento Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 716.50M | 167.80M | $ -203.54M | -1.91 | - | 63.33M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Sorrento Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/24/2020 | 16:41 | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3/a) |
| 1/24/2020 | 06:04 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) |
| 1/24/2020 | 06:00 | Edgar (US Regulatory) | Notice of Effectiveness (effect) |
| 1/23/2020 | 06:02 | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3/a) |
| 1/17/2020 | 17:09 | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3) |
| 1/17/2020 | 16:18 | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3/a) |
| 1/10/2020 | 07:01 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SRNE Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.41 | 4.5199 | 3.90 | 4.21 | 3,055,954 | -0.14 | -3.17% |
| 1 Month | 3.21 | 5.92 | 3.16 | 4.31 | 5,643,999 | 1.06 | 33.02% |
| 3 Months | 1.54 | 5.92 | 1.45 | 3.59 | 6,765,936 | 2.73 | 177.27% |
| 6 Months | 2.45 | 5.92 | 1.39 | 3.29 | 3,661,122 | 1.82 | 74.29% |
| 1 Year | 2.11 | 6.50 | 1.39 | 3.45 | 2,845,711 | 2.16 | 102.37% |
| 3 Years | 5.20 | 10.65 | 1.39 | 4.25 | 2,020,552 | -0.93 | -17.88% |
| 5 Years | 9.98 | 26.80 | 1.39 | 4.97 | 1,359,605 | -5.71 | -57.21% |
Sorrento Therapeutics Description
| Sorrento Therapeutics Inc is a biotechnology company focused on the development of novel immunotherapies for oncology and autoimmune/inflammation diseases. The antibody technologies target various locations: extracellular, intracellular, and membrane-bound antigens. The product portfolio consists of BioSimilar/BioBetter antibodies, CAR-T programs for treatment of solid tumors, adoptive cellular therapies, immuno-oncology mAbs, and antibody drug conjugates. |
